{"disease":{"id":"cancer-pelvis","name":"cancer pelvis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03662204","title":"Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":5133,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT06469229","title":"Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT03244384","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":739,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05092958","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":654,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00942331","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02045381","title":"Optimization of MRI for Radiation Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT02496208","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04865939","title":"Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06040762","title":"A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04724018","title":"Sacituzumab Govitecan Plus EV in Metastatic UC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04620239","title":"ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Steba Biotech S.A.","has_results":false},{"nct_id":"NCT03397394","title":"Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":97,"lead_sponsor_name":"pharmaand GmbH","has_results":true},{"nct_id":"NCT01347697","title":"Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT06764095","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03237780","title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06427993","title":"Urine DNA Methylation Detection for Hematuria Evaluation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":71,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT07087860","title":"Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01326871","title":"A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Altor BioScience","has_results":true},{"nct_id":"NCT02812420","title":"Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03513952","title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04008537","title":"Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device","phase":"NA","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT04940299","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00749892","title":"Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04398368","title":"Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04963153","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03133286","title":"Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)","phase":"","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"DxTerity Diagnostics","has_results":false},{"nct_id":"NCT02300610","title":"Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT06630247","title":"A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04848519","title":"Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04953104","title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04620603","title":"Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03617913","title":"Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04006691","title":"Efficacy and Safety of UGN-101 in Recurrent Patients","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"UroGen Pharma Ltd.","has_results":false},{"nct_id":"NCT05494411","title":"Named Patient Program for Mitomycin for Pyelocalyceal Solution","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"UroGen Pharma Ltd.","has_results":false}],"total":34},"guidelines":[],"source":"Drug Landscape verified database"}